Clinical Trial Update: Study of Acalabrutinib and Tafasitamab in MZL Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of acalabrutinib and tafasitamab in patients with marginal zone lymphoma; the study is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Monjuvi (tafasitamab)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING